TGFB1 and metabolic dysfunction-associated steatohepatitis: Based on the results that ZM241385 treatment, but not CGS21680, reversed the TGF-β1-induced increase in profibrotic markers, we sought to discover therapeutic candidates for the treatment of hepatic fibrosis in MASH conditions through inhibition of the A2aAR signaling pathway.